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ABSTRACT Tenofovir disoproxil fumarate (TDF), a prodrug of tenofovir, has oral
bioavailability (25%) limited by intestinal transport (P-glycoprotein), and intestinal
degradation (carboxylesterase). However, the inﬂuence of luminal pancreatic en-
zymes is not fully understood. Physiologically based pharmacokinetic (PBPK) model-
ing has utility for estimating drug exposure from in vitro data. This study aimed to
develop a PBPK model that included luminal enzyme activity to inform dose reduc-
tion strategies. TDF and tenofovir stability in porcine pancrelipase concentrations
was assessed (0, 0.48, 4.8, 48, and 480 U/ml of lipase; 1 mM TDF; 37°C; 0 to 30 min).
Samples were analyzed using mass spectrometry. TDF stability and permeation data
allowed calculation of absorption rates within a human PBPK model to predict
plasma exposure following 6 days of once-daily dosing with 300 mg of TDF. Re-
gional absorption of drug was simulated across gut segments. TDF was degraded by
pancrelipase (half-lives of 0.07 and 0.62 h using 480 and 48 U/ml, respectively). Pre-
viously reported maximum concentration (Cmax; 335 ng/ml), time to Cmax (Tmax;
2.4 h), area under the concentration-time curve from 0 to 24 h (AUC0–24; 3,045 ng ·
h/ml), and concentration at 24 h (C24; 48.3 ng/ml) were all within a 0.5-fold differ-
ence from the simulated Cmax (238 ng/ml), Tmax (3 h), AUC0–24 (3,036 ng · h/ml), and
C24 (42.7 ng/ml). Simulated TDF absorption was higher in duodenum and jejunum
than in ileum (p0.05). These data support that TDF absorption is limited by the ac-
tion of intestinal lipases. Our results suggest that bioavailability may be improved by
protection of drug from intestinal transporters and enzymes, for example, by coad-
ministration of enzyme-inhibiting agents or nanoformulation strategies.
KEYWORDS tenofovir disoproxil fumarate, physiologically based pharmacokinetic
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Human immunodeﬁciency virus (HIV) is the cause of a currently incurable diseasewhich constitutes a serious global health crisis. Oral antiretroviral therapy is the
mainstay of current therapy and involves coadministration of drugs targeting multiple
viral targets. Both drug-related adverse reactions and drug resistance have led to the
development of newer antiretroviral drugs and drug classes. However, the cost and
dosing schedule of treatments are a signiﬁcant concern in low- and middle-income
countries (L&MICs). Several effective antiretroviral drugs are now manufactured as
generics and are marketed with signiﬁcant cost savings to payers (1, 2).
Tenofovir disoproxil fumarate (TDF), a prodrug of tenofovir (TFV), is a cornerstone of
ﬁrst-line treatment in low-income and middle-income countries. TDF is a nucleotide
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reverse transcriptase inhibitor, which prevents viral DNA chain lengthening and repli-
cation (3) (Fig. 1). During preclinical development, TFV demonstrated low oral bioavail-
ability (around 13%) (4), and TDF was developed to improve this by removing charged
regions and increasing lipophilicity. However, the oral bioavailability of TDF was only
moderately improved and is estimated at around 25% in fasted subjects (5, 6). Sub-
stantially improving the bioavailability of TDF would provide signiﬁcant cost savings in
L&MICs. In order to achieve this, it is important to understand the causes of low TDF
bioavailability and to formulate potential targeting strategies.
Using Caco-2 cell monolayers as a model for the intestinal epithelial surface, the
drug efﬂux transporter ABCB1 has been shown to readily transport TDF (7). As ABCB1
is involved in the elimination of substrates from the enterocytes of the intestine back
into the luminal space, it is hypothesized that inhibitors of ABCB1 may improve TDF oral
absorption. However, this ABCB1 inhibitory effect was not observed in situ using
perfusion studies with rats (8). The signiﬁcance of this ﬁnding is not clear due to the
signiﬁcantly faster TDF degradation in rat duodenal and ileal enterocytes than in
corresponding human enterocytes (9).
Previous studies have investigated the impact of coadministered HIV protease
inhibitors on TFV pharmacokinetics (7). Ritonavir-boosted protease inhibitors atazana-
vir, lopinavir, darunavir, and saquinavir all showed a modest increase in TFV exposure
when coadministered with TDF. Protease inhibitors show various degrees of ABCB1
inhibition in vitro. Therefore, the same study also investigated the impact of these drugs
on ABCB1-mediated transport of TDF. Darunavir, which in patients led to a 22%
increase in TFV exposure, had no impact on TDF transport in vitro. In the case of the
interactions observed with protease inhibitors and possibly other drugs, additional
bioavailability-related mechanisms are likely to be involved alongside ABCB1.
TDF is rapidly metabolized to TFV in the presence of rat intestinal microsomes (8).
It was hypothesized that carboxylesterase was responsible for this metabolism, and
further investigations showed improved drug stability in the presence of certain natural
fruit extracts and pharmacological esters. Protease inhibitors have shown various
degrees of carboxylesterase inhibition, and this enzyme may therefore be involved in
interactions between TDF and these drugs.
FIG 1 Process of converting the prodrug TDF to TFV and ultimately to the active substance TFV diphosphate.
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Pancreatic enzymes, including lipase, amylase, and trypsin, are released into the
duodenum and are involved in the breakdown of ingested food in preparation for
nutrient absorption. Pancreatic lipase is known to hydrolyze ester bonds (10), but the
ability of lipase to metabolize TDF by ester-linked chain removal has not been previ-
ously investigated.
The initial aim of this study was to determine in vitro the extent of TDF metabolism
by pancreatic lipase. These data were combined with previous information on TDF
ABCB1-mediated transport and carboxylesterase metabolism to create a physiologically
based pharmacokinetic (PBPK) model with informed absorption mechanisms involving
all these processes. The model generated was then used to estimate the relative
importance of these factors in TDF absorption, providing a platform to postulate
possible dose reduction strategies.
RESULTS
Stability of TDF in pancrelipase. The breakdown of TDF was determined at various
concentrations of lipase. The half-lives of TDF were determined as 4.0 min in 480 U/ml
of lipase and 37.5 min in 48 U/ml of lipase. TDF was stable in 4.8 U/ml of lipase and
below; therefore, half-life was not determined at these concentrations. Data were used
to generate the following equation, relating lipase concentration to TDF stability, which
was used to inform the PBPK model: TDF1/2  0.0013  [lipase]  0.6863, where
TDF1/2 is the half-life of TDF (in hours) and [lipase] is the concentration of lipase in the
intestine (in units per milliliter). To conﬁrm the role of lipase in TDF degradation,
selective inhibition of pancreatic enzymes was performed and the inﬂuence on TDF
half-life was evaluated. Coincubation of TDF with lipase inhibitor orlistat resulted in a
33% increase in TDF half-life (16.0 min) compared to that with inhibitor-free incubation
(12.0 min; P  0.02), whereas no alteration in TDF half-life was observed with coincu-
bation with the amylase inhibitor acarbose (12.6 min; P 0.66) or trypsin inhibitor type
1-S from Glycine max (soybean) (12.7 min; P  0.23).
Model veriﬁcation. The 300-mg once-daily steady-state TFV pharmacokinetic study
by Barditch-Crovo et al. showed variability in the median pharmacokinetic parameters
maximum concentration (Cmax), time to maximum concentration (Tmax), and area under
the concentration-time curve from 0 to 24 h (AUC0–24) assessed between days 8, 15,
and 35 of the study (6). Therefore, a mean and standard deviation (SD) between these
assessment days were calculated and used for comparison with simulated data. The
clinical Cmax (335 ng ml1), Tmax (2.4 h), and AUC0–24 (3,045 ng · h ml1) were all within
a 0.5-fold difference of the simulated Cmax (238 ng ml1; 0.41-fold higher), Tmax (3 h;
0.2-fold lower), and AUC0–24 (3,036 ng · h ml1; 0-fold difference). The observed median
TFV concentration at 24 h (C24) following 7 days of once-daily oral dosing at 300 mg
was 48.3 ng ml1, which was within the acceptable range of the median simulated TDF
C24 of 42.7 ng ml1 (Fig. 2A). The terminal plasma half-lives of TFV were determined as
11.7 h and 8.5 h from the median clinical and simulated pharmacokinetic data,
respectively, following 7 days of 300-mg once-daily oral dosing. The simulated mean
bioavailability of 300 mg of orally dosed TDF was 21.2%  3.3% (range, 13.1% to
27.6%). This estimation of oral bioavailability slightly underpredicted the 25% value
estimated to be bioavailable from clinical studies. To validate the robustness of the
model further, simulations were performed as described above but using alternative
TDF oral dose sizes (75 mg, 150 mg, and 600 mg) and plasma concentration curves
compared with previous clinical data (6). For the 75-mg TDF dose, the clinical Cmax (53
ng ml1) and Tmax (2.5 h) were within a 0.5-fold difference of the simulated Cmax (51 ng
ml1; 0.03-fold higher) and Tmax (3 h; 0.2-fold lower) (Fig. 2B). The AUC0–24 and C24 for
the 75-mg dose could not be determined from the clinical data, as TFV was undetect-
able at the 0- and 24-h time points on the plasma concentration curve. Therefore,
clinical AUC1–12 (480 ng · h ml1) and C12 (34 ng ml1) were compared to simulated
AUC1–12 (488 ng · h ml1; 0.02-fold lower) and C12 (28 ng ml1; 0.21-fold higher) (Fig.
2B). For the 150-mg TDF dose, the clinical Cmax (135 ng ml1), Tmax (2.5 h), AUC0–24
(1,581 ng · h ml1), and C24 (29 ng ml1) were all within a 0.5-fold difference of the
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simulated Cmax (112 ng ml1; 0.21-fold higher), Tmax (2 h; 0.25-fold higher), AUC0–24
(1,581 ng · h ml1; 0-fold difference), and C24 (23 ng ml1; 0.26-fold higher) (Fig. 2C).
For the 600-mg TDF dose, the clinical Cmax (618 ng ml1), Tmax (2.5 h), AUC0–24 (6,166
ng · h ml1), and C24 (111 ng ml1) were all within a 0.5-fold difference of the simulated
Cmax (574 ng ml1; 0.08-fold higher), Tmax (2 h; 0.25-fold higher), AUC0–24 (7,547 ng · h
ml1; 0.18-fold lower), and C24 (106 ng ml1; 0.05-fold higher) (Fig. 2D).
Simulations of TDF and TFV fractional absorption. The regional intestinal ab-
sorption of TDF and TFV was simulated over 24 h in 100 virtual subjects following a
single 300-mg oral dose of TDF (Fig. 3). The majority of drug entering the systemic
FIG 2 Validation of the physiologically based pharmacokinetic model strategy against clinical data of TDF once-daily, day 7 proﬁles for
dose sizes of 300 mg (A), 75 mg (B), 150 mg (C), and 600 mg (D). Data are from reference 6.
FIG 3 Amounts of TDF and tenofovir absorbed via each intestinal segment following a single 300-mg
oral dose of TDF (mean  SD 24 h postdose). J1, jejunum section 1; J2, jejunum section 2; I1, ileum
section 1; I2, ileum section 2; I3, ileum section 3.
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circulation was predicted to be accounted for by absorption of TDF directly, predom-
inantly via the duodenum (11.7 mg) and section 1 of the jejunum (11.6 mg). Compared
to absorption of TDF, overall absorption of TFV was predicted to be minor and varied
from 0.15 mg in the duodenum to 1.19 mg in section 2 of the jejunum.
Simulations of tenofovir plasma concentrations following inhibition of intes-
tinal ABCB1, carboxylesterase (CES), and luminal lipase. Data were found to be
nonnormally distributed, so a Mann-Whitney U test was used to determine signiﬁcance.
The median tenofovir AUC0–24 (5th to 95th centile) of the control group (3,036 [1,752
to 4,762] ng · h ml1) was signiﬁcantly less than those of the other groups following
inhibition of ABCB1 (4,480 [2,538 to 7,228] ng · h ml1; P  0.01), ABCB1 plus
carboxylesterase (6,018 [3,514 to 10,976] ng · h ml1; P  0.01), lipase (12,873 [9,020 to
20,827] ng · h ml1; P  0.01), ABCB1 plus lipase (17,322 [12,752 to 26,226] ng · h ml1;
P  0.01), and ABCB1 plus carboxylesterase plus lipase (19,250 [14,215 to 29,208] ng ·
h ml1; P  0.01) (Table 1).
Simulations of dose reduction strategies. Further simulations were performed in
which the TDF dose was reduced in groups with inhibited factors, with the aim of
achieving a median tenofovir AUC0–24 similar (within 10% difference) to that observed
in the control group. Comparable tenofovir exposure was observed in all simulated
groups following speciﬁc dose reductions in each case (Table 2). The median AUC0–24
(5th to 95th centile) following inhibition of ABCB1 (200-mg dose; 2,897 [1,678 to 4,603]
ng · h ml1), ABCB1 plus carboxylesterase (150-mg dose; 3,002 [1,900 to 4,536] ng · h
ml1), lipase (90-mg dose; 3,337 [2,245 to 5,341] ng · h ml1), ABCB1 plus lipase (60-mg
dose; 3,279 [2,366 to 4,950] ng · h ml1), and ABCB1 plus carboxylesterase plus lipase
(50-mg dose; 3,133 [2,286 to 4,751] ng · h ml1) were all within a 10% difference from
that of the control group (3,036 [1,752 to 4,762] ng · h ml1).
DISCUSSION
In this study, we have established that TDF is unstable in the presence of physio-
logically relevant concentrations of pancrelipase. The most likely mechanism of this
degradation is ester bond cleavage that ﬁrst results in the TFV monoester and ﬁnally in
TFV. As this process occurs in the luminal ﬂuid prior to drug absorption, it is hypoth-
esized that luminal lipase activity inﬂuences TDF bioavailability in humans. To investi-
TABLE 1 Simulated median pharmacokinetic parameters of tenofovir following inhibition
of factors involved in drug absorption of TDFa
Inhibited factor(s)
Cmax
(ng ml1) Tmax (h)
AUC0–24
(ng · h ml1)
C24
(ng ml1)
None (control) 238 3 3,036 43
ABCB1 377 2 4,480 51
ABCB1  CES 538 2 6,018 68
Lipase 1,013 3 12,873 199
ABCB1  lipase 1,409 3 17,322 235
ABCB1  CES  lipase 1,642 3 19,250 228
aParameters were determined following 6 days of once-daily oral dosing of 300 mg of TDF in 100 healthy
male subjects.
TABLE 2 Dose reduction strategies following inhibition of factors involved in drug
absorption of TDFa
Inhibited factor(s)
Dose
size (mg)
AUC0–24
(ng · h ml1)
% difference
from control
None (control) 300 3,036 NA
ABCB1 200 2,897 5
ABCB1  CES 150 3,002 1
Lipase 90 3,337 10
ABCB1  lipase 60 3,279 8
ABCB1  CES  lipase 50 3,133 3
aParameters were determined following 6 days of once-daily oral dosing of TDF in 100 healthy male
subjects. NA, not applicable.
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gate this, the impact of luminal lipase was included in the PBPK model to estimate
plasma TFV concentrations. Simulations suggest that the included factors contribute to
the TFV exposure seen in subjects, with luminal lipase having a signiﬁcant impact. In
addition to results generated in this study, there is supporting evidence that lipase may
be a relevant factor in determining TFV bioavailability. Protease inhibitors are able to
inhibit lipase activity in vitro (11), and this process may be involved in the interactions
seen between TDF and these drugs (possibly in addition to its known inhibition of
transporters). Additionally, TDF exposure was increased 40% in human subjects when
TDF was taken with a high-fat meal, whereas no comparable effect was seen with a
low-fat meal (3). Although it is common to see improved biovavailability of highly
lipophilic and insoluble drugs when they are taken with a fatty meal, TDF is reasonably
soluble in intestinal ﬂuid. Alternatively, it can be hypothesized that the increased fat in
the intestinal ﬂuid limits availability of lipase active sites for TDF metabolism. However,
this competition has not been assessed and requires further empirical conﬁrmation.
We have successfully employed PBPK modeling to include a variety of factors that
inﬂuence TDF absorption. However, due to existing knowledge gaps and the complex-
ities of biological processes involved in TFV pharmacokinetics, there are limitations to
this approach, and it is important that these limitations are addressed. The simulations
were undertaken assuming a population of fasted subjects, and the inﬂuence of
ingested food and fats was not considered. This was due to incomplete information on
the effects of food and fats on intestinal lipase activity and the inﬂuence of this on TDF
stability. It was assumed that lipase was active only in the small intestine compartments
and that the level of activity did not vary between these compartments in individual
subjects. Per amount of enzyme, the activity levels of the lipase were assumed to be
similar in both in vitro and in vivo environments, and in the in vitro experiments we used
fasted simulated small intestinal ﬂuid (FSSIF) to replicate the environment in fasted-
state luminal ﬂuid. Additionally, the use of porcine pancrelipase was chosen due to the
well-characterized enzymatic activity of the product, where precise units of all enzymes
(i.e., activities of lipase, amylase, and trypsin) per weight of substance were known,
whereas human pancreatic ﬂuids available to us did not provide the required informa-
tion needed for utilization in the PBPK model. The distribution levels and activity levels
of carboxylesterase protein in different sections of the intestine are unknown; therefore,
it was assumed that the Caco-2 cell intestinal model was a suitable surrogate system.
Reformulation of TDF offers a strategy to improve bioavailability. There are cases
in which multiple formulations of an antiretroviral are available, often for speciﬁc
scenarios such as in pediatric treatment. Comparison studies have shown that formu-
lation composition can signiﬁcantly inﬂuence antiretroviral pharmacokinetics (1).
Extended-release formulations have proven beneﬁcial in many diseases and may have
the potential to protect TDF from luminal enzymes. Inhibition of ABCB1 or carboxyles-
terase alone is unlikely to have a dramatic effect on TFV bioavailability, but a more
holistic approach to inhibit multiple proteins (including lipase) may be more successful.
This is somewhat supported by the modest increase in TFV exposure observed on
coadministration with boosted protease inhibitors, and a more target-driven approach
may achieve greater increases. Emerging nanotechnologies may also provide tailor-
made opportunities to encapsulate and protect TDF from degradation until absorption
is complete (12).
MATERIALS AND METHODS
Determination of TDF stability in pancrelipase. The stability of 1 mM TDF was assessed in triplicate
in a range of lipase concentrations (0, 0.48, 4.8, 48, and 480 U/ml) using porcine pancrelipase. The
medium used to perform experiments was fasted simulated small intestinal ﬂuid (FSSIF; 3 mM sodium
taurocholate, 0.2 mM lecithin, 34.8 mM sodium hydroxide, 68.62 mM sodium chloride, 19.12 mM maleic
acid, 1 liter of deionized water, and hydrogen chloride added dropwise to achieve pH 6.5), and TDF
concentrations were assessed at 0, 5, 10, 15, 20, and 30 min. Parallel experiments were performed to
identify the speciﬁc enzymes involved in TDF degradation, where saturating concentrations of inhibitors
of lipase (100 g/ml of orlistat), amylase (1 mg/ml of acarbose), and trypsin (1 mg/ml of type 1-S trypsin
inhibitor from soybean) (13) were coincubated with 20 g/ml of TDF and alterations in TDF half-life were
determined in the presence of a mix of porcine pancreatic enzymes (100 U/ml of lipase, 540 U/ml of
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amylase, and 340 U/ml of trypsin). All experiments were performed at 37°C, and samples were processed
and analyzed at Scynexis (Durham, NC) using liquid chromatography-tandem mass spectrometry (LC-
MS/MS). The column used was a Synergi Polar RP column (2.0 by 150 mm; 4 m; Phenomenex) kept at
60°C. Mobile phase A was 96% water–3% acetonitrile–1% acetic acid, and mobile phase B was 3%
water–96% acetonitrile–1% acetic acid. The ﬂow rate was 600 l/min and consisted of 100% mobile
phase A between 0 and 1 min, 2% mobile phase A–98% mobile phase B at 2 min, 2% mobile phase
A–98% mobile phase B at 3 min, 100% mobile phase A at 3.1 min, and 100% mobile phase A at 4 min.
TDF was detected in positive mode, Q1 mass was 520.1, and Q3 mass was 270 using collision energy 34.
Labetalol was used as an internal standard.
Model construction. The PBPK model was created using SimBiology v.3.3, a product of Matlab v.8.2
(MathWorks, Natick, MA). The aim of the PBPK model was to simulate the steady-state pharmacokinetics
of TFV in humans following 6 days of once-daily administration of 300 mg of TDF. In particular, the
aspects potentially relevant to TDF absorption (solubility, lipase activity, carboxylesterase activity, and
ABCB1 activity) were included to simulate the relative importance of each factor.
System parameters. The basic structure of the PBPK model is based on a previously published
model created by us (14). Demographic factors of virtual male subjects between the ages of 18 and 60
(height, weight, body mass index, and body surface area) were taken from published literature and used
in allometric equations to calculate individual organ volumes (15). The volume and rate of blood
circulation in each simulated subject were calculated as previously described (14). The model was created
with the following assumptions: (i) tissue compartments were treated as well-stirred compartments with
instant distribution of drug, (ii) drug was not absorbed from the stomach compartment, (iii) the rate of
drug absorption from the cecum and colon was reduced to 10-fold less than would be observed in the
small intestine under the same conditions, and (iv) the model is blood ﬂow limited. The physiological
factors relevant for drug absorption in the intestinal compartments are based on the advanced
compartmental absorption and transit (ACAT) model and are given in Table 3 (16).
Drug parameters. (i) Solubility of TDF in the luminal ﬂuid. In order to account for potential
solubility-induced absorption limitations, the solubility of TDF was measured by Corealis Pharma
(Quebec, Canada) in a physiologically relevant range of buffered pH solutions. Solubility of TDF was high
at 9,300, 4,800, and 6,200 mg/liter in buffered solutions of pHs 2, 4.5, and 8, respectively. These
results were then used to derive the following quadratic equation to calculate the pH-dependent
limitations to TDF luminal solubility (in milligrams per liter) in the PBPK model intestinal compart-
ments: TDFs  (366.67  [IpH]2) – (4,183.33  IpH)  16,200, where TDFs is the maximum possible
solubility of TDF (in milligrams per liter) and IpH is the pH of the intestinal segment ﬂuid.
Only soluble TDF, which was continually determined throughout simulations in each intestinal
segment, was available for absorption in the PBPK absorption model.
(ii) Stability of TDF in the luminal ﬂuid. Intestinal lipase concentrations were acquired from the
literature and included in the small intestine segments of the PBPK model (duodenum, jejunum, and
ileum) (17). Each simulated fasted subject was given a physiologically relevant concentration of luminal
lipase which was randomly assigned within the ranges obtained from published literature of between
100 and 400 U/ml. Using the in vitro metabolism data generated in this study, an equation was then
developed establishing the relationship between lipase concentration and drug half-life, as given in
Results. The lipase-dependent rate of elimination was then determined for each simulated subject and
the degraded TDF was assumed to be converted to TFV, which either is absorbed or passes along and
out of the intestine, as detailed below.
(iii) Absorption of TDF and TFV. TDF permeation through a Caco-2 cell monolayer has been
previously investigated, and the apparent permeability (Papp) was found to be drug concentration
dependent (7). The authors hypothesized that this was the result of active transport saturation (specif-
ically, saturation of ABCB1) when higher TDF concentrations were added to the receiver compartment.
To inform the current model of this scenario, this relationship between TDF concentrations and Papp was
continuously redetermined in each intestinal segment using the following polynomial equation, derived from
a previous study (7): TDFPapp  1.9  1026  [TDFconc]6  3.3  1022  [TDFconc]5 – 2.2  1018 
[TDFconc]4 7.5 1015 [TDFconc]3 1.3 1011 [TDFconc]2 1.1 108 [TDFconc] 1.6 107,
TABLE 3 Physiological factors relevant for simulating the oral absorption of TFV disoproxil
and TFV in the PBPK model
Segment pH
Vol
(ml)
Radius
(cm)
Transit
time (h)
Absorption
scaling
Stomach 1.3 46.56 NAa 0.25 0
Duodenum 6 41.56 1.53 0.26 1
Jejunum 1 6.2 154.2 1.45 0.93 1
Jejunum 2 6.4 122.3 1.29 0.74 1
Ileum 1 6.6 94.29 1.13 0.58 1
Ileum 2 6.9 70.53 0.98 0.42 1
Ileum 3 7.4 49.83 0.82 0.29 1
Cecum 6.4 47.49 3.39 4.19 1
Colon 6.8 50.33 2.41 12.57 0.1
aNA, not applicable.
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where TDFPapp is the estimated TDF Papp value at a speciﬁc concentration of TDF and TDFconc is the
concentration of TDF.
Using previously established equations, Papp was used to generate the rate of drug absorption in the
model (18, 19). Intestinal absorption of TFV, the breakdown product of TDF occurring via luminal lipase,
was included. The rate of intestinal TFV absorption was determined by scaling the Papp value of 0.41
cm  106 s1 determined previously in MDCK monolayers (20, 21).
(iv) Distribution of TFV. The volume of distribution of TFV was simulated considering the volume
of distribution of 0.813 liter/kg described in population pharmacokinetic studies (22), and the tissue
distribution was determined using previously published equations (23, 24).
(v) Clearance of TFV. TFV is predominantly eliminated from the body unchanged via the kidneys. In
order to account for this loss, clearance of TFV was included in the model. The multiple physiological
factors involved in the elimination of TFV, such as the effect of drug transporters and tubular reabsorp-
tion, have not been fully characterized, making a mechanistic prediction of TFV renal elimination difﬁcult.
Therefore, a TFV total clearance rate of 0.066 liter/h/kg was derived from a previous population
pharmacokinetic study and was included in our model (6).
Model veriﬁcation. To verify the model, pharmacokinetic data from simulations were compared to
clinical data. Following 6 days of once-daily dosing of 300 mg of TDF in 100 simulated subjects, median
TFV Cmax, Tmax, AUC0–24, and C24 were calculated and contrasted to steady-state pharmacokinetics
observed in real subjects, taken from a randomized, double-blind, placebo-controlled, escalating-dose
study of four doses (75, 150, 300, and 600 mg given once daily) with 8 or 9 subjects in each group (6).
Additionally, the terminal plasma half-life of TDF was estimated from simulated concentration plots and
compared to the half-life generated from clinical data. The bioavailability of orally administered TDF is
estimated at around 25% of the total dose (25), and the bioavailability of 300 mg of orally administered
TDF was determined from our simulations (mean  standard deviation, with minimum and maximum
range) as a comparison to further validate the model. As a predetermined measure of success for the
model validation, a 0.5-fold difference or less between clinical and predicted pharmacokinetic parame-
ters was deemed acceptably accurate (26, 27). Pharmacokinetic parameters were determined by non-
compartmental analysis using PK Solutions 2.0 (Summit Research Services, UK).
To validate the robustness of the model further, simulations were performed as described above but
using alternative TDF oral dose sizes (75 mg, 150 mg, and 600 mg). Pharmacokinetic parameters (median
TFV Cmax, Tmax, AUC0–24, and C24) were generated from these simulations and were compared to available
clinical pharmacokinetic data where these dose sizes were utilized (6).
Assessment of regional absorption of TDF and TFV. The regional absorption of TDF and TFV was
simulated in 100 virtual subjects following a single 300-mg oral dose of TDF. Mean absorption amounts
(in milligrams) with standard deviations were determined 24 h postdose in duodenum, jejunum section
1 (j1), jejunum section 2 (j2), ileum section 1 (i1), ileum section 2 (i2), ileum section 3 (i3), cecum, and
colon (Table 3).
Prediction of TFV pharmacokinetics following inhibition of factors involved in absorption. In
order to determine the inﬂuence of intestinal ABCB1, CES, and lipase on tenofovir exposure, each factor
was individually (with the exception of CES) and in combination removed from simulations and the
pharmacokinetics of TFV were determined for each combination. In the case where lipase activity in the
model was eliminated, simulations were performed where the intestinal TDF1/2 was 0 min. In the case where
ABCB1 activity was inhibited, simulations were performed using a TDF Papp value of 3.6 cm  106 s1,
taken from a previous study (7). In the case where ABCB1 and CES activities in the model were inhibited,
simulations were performed using a TDF Papp value of 9.41 cm  106 s1, taken from a previous Caco-2
cell permeation study in which inhibition of ABCB1 and CES activity was achieved using TPGS (ABCB1
inhibitor) and 1 mM propylparaben (CES inhibitor) (7, 20). In each group, mean tenofovir Cmax, Tmax,
AUC0–24, and C24 were calculated following 6 days of once-daily dosing with 300 mg of TDF in 100
simulated subjects.
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